Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-k, sec-filing
TL;DR
Telomir Pharma filed an 8-K, but details are scarce.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself. The company is incorporated in Florida and headquartered in Miami.
Why It Matters
This 8-K filing indicates that Telomir Pharmaceuticals has reported an event requiring immediate disclosure to the SEC, though the specifics are not detailed in the provided text.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, making it difficult to assess the immediate impact or risk.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- August 27, 2025 (date) — Date of Report
- Miami, Florida (location) — Principal Executive Offices
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.
When was this 8-K filing submitted to the SEC?
The filing was made on August 27, 2025.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the SEC file number for Telomir Pharmaceuticals, Inc.?
The SEC file number is 001-41952.
What is the IRS Employer Identification Number (EIN) for Telomir Pharmaceuticals, Inc.?
The EIN for Telomir Pharmaceuticals, Inc. is 87-2606031.
Filing Stats: 774 words · 3 min read · ~3 pages · Grade level 16 · Accepted 2025-08-27 16:01:33
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001641172-25-025688.txt ( ) — 204KB
- telo-20250827.xsd (EX-101.SCH) — 3KB
- telo-20250827_lab.xml (EX-101.LAB) — 33KB
- telo-20250827_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: August 27, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer